Latest news
- Sep 21, 2017 – Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
- Sep 13, 2017 – Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB
- Aug 23, 2017 – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
Calendar
- Oct 31, 2017 - Nov 2, 2017 - European Antibody Congress, Basel
- Nov 6, 2017 - Nov 9, 2017 - BIO-Europe, Berlin
- Nov 8, 2017 - Nov 12, 2017 - SITC (Society for Immunotherapy of Cancer) 32nd Annual Meeting, National Harbor, US
- Nov 13, 2017 - Nov 17, 2017 - PEGS Europe, Protein and Antibody Engineering Summit, Lisbon
- Nov 14, 2017 - Nov 16, 2017 - 3rd Annual ICI Europe Summit, Munich
Strong pipeline
Alligator Bioscience has a broad project portfolio with several antibody-based immuno-oncology candidates. The company’s most advanced project, ADC-1013, in clinical Phase I being developed with partner Janssen Biotech, and the preclinical product candidates ATOR-1015, ATOR-1017, och ALG.APV-527.